Followers | 8 |
Posts | 2087 |
Boards Moderated | 0 |
Alias Born | 07/31/2006 |
Monday, June 16, 2014 11:48:38 AM
Today's full post-libel intraday share price recovery makes it clear that any harm caused to shareholders as a result of the publication of the libelous article in January is 100% the result of and responsibility of the author and publisher of that libelous article, and not the responsibility of NanoViricides.
The fact of this full recovery in share price undercuts all of factual misstatements and specious assertions made in the article, and shows NanoViricides to be not responsible on a material basis for the share price declines of the past five months (i.e., if the contents of the article were in any sense true, share price would not have recovered). Moreover, today's share price recovery shows NanoViricides to themselves be a victim of the publishing of the article, and a victim of the price declines, not their cause.
Anyone holding shares through this entire ordeal have today been made whole. They have not been harmed. Only those shareholders who panicked and sold shares on that day or subsequent days have been harmed, and that harm is the responsibility of the author and publisher of the libelous article, "Pump Terminator" and "Seeking Alpha".
No proceedings against NanoViricides were ever started by those half dozen opportunistic law firms listed by NewMoney, and none ever will be. Clearly, no ambulance chasing law firm would consider beginning proceedings against NanoViricides when the only evidence of harm is the direct result of publishing of the article itself. The cause of action would be against the author and/or publisher, brought both by damaged shareholders and soon by NanoViricides itself.
Best to all.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM